Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Histamine analogue (vestibular) Pregnancy: As a precautionary measure it is preferable to avoid betahistine during pregnancy - there are no adequate data in pregnant women. It is not known whether betahistine is excreted in human milk; weigh the importance of the drug to the mother against the benefits of nursing and the potential risks to the child.

Betahistine dihydrochloride

Brand names: Serc

Betahistine dihydrochloride is an oral histamine analogue used to reduce the frequency and severity of vertigo, tinnitus and hearing loss associated with Ménière's disease.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 16 mg three times daily initially
Route: Oral
Frequency: Three times daily, preferably with meals
Adults (including the elderly): initially 16 mg three times daily taken preferably with meals. Maintenance doses are generally in the range 24-48 mg daily. Swallow the tablets with water. Paediatric population: betahistine should not be used in children aged below 18 years due to insufficient data on safety and efficacy. Elderly: no dose adjustment necessary (limited clinical trial data; extensive post-marketing experience). Hepatic impairment: no dose adjustment appears necessary per post-marketing experience. Product: Betahistine Dihydrochloride 16 mg Tablets.

Dose adjustments

Renal

No specific clinical trials in renal impairment, but according to post-marketing experience no dose adjustment appears to be necessary

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Phaeochromocytoma
  • Hypersensitivity to the active substance or to any of the excipients

Side effects

  • Nausea (common)
  • Dyspepsia (common)
  • Headache (common)
  • Mild gastric complaints - vomiting, gastrointestinal pain, abdominal distension and bloating (frequency not known; often managed by taking the dose with meals or lowering the dose)
  • Hypersensitivity reactions including anaphylaxis (frequency not known)
  • Cutaneous and subcutaneous hypersensitivity reactions - angioneurotic oedema, urticaria, rash, pruritus (frequency not known)

Interactions

  • MAO inhibitors, including MAO-B selective (e.g. selegiline) - in vitro data indicate inhibition of betahistine metabolism; caution with concomitant use
  • Antihistamines - as betahistine is an analogue of histamine, interaction may in theory affect the efficacy of one of these drugs
  • No in-vivo interaction studies have been performed; no in-vivo inhibition of cytochrome P450 enzymes expected

Clinical monograph

How it works

It acts as a weak histamine H1 agonist and H3 antagonist, thought to improve cochlear and vestibular microcirculation and modulate central vestibular signalling.

Prescribing in practice

  • Use with caution in patients with active or a history of peptic ulcer disease, and in those with phaeochromocytoma; it should be avoided where there is known hypersensitivity.
  • It may worsen symptoms in asthma, so monitor patients with asthma closely when starting treatment.
  • Benefit develops gradually over weeks of regular dosing, so therapy should be given an adequate trial before judging response.

Monitoring

Monitor symptomatic response and tolerability over weeks; no routine laboratory monitoring is required.

Counselling the patient

  • Take with or after food to reduce stomach upset.
  • Improvement can take several weeks, so keep taking it regularly.
  • Report worsening wheeze, indigestion or stomach pain.

Evidence & guidelines

Betahistine is widely used for Ménière's disease, though high-quality trial evidence for symptom control is limited and mixed.

Reference: NICE CKS Ménière's; ENT UK; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways